Form 4: Ocular Therapeutix CDO Granted Significant Equity Awards

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, was granted 79,112 restricted stock units and 240,932 stock options, aligning his incentives with long-term company performance.

Summary

• Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc. (OCUL), was granted 79,112 restricted stock units (RSUs) on January 2, 2026.
• These RSUs represent a right to receive one share of common stock per RSU and will vest over three years, with 1/3 vesting on the one-year anniversary of the grant date and an additional 1/3 vesting at the end of each successive one-year period thereafter, subject to continued service.
• Kaiser also acquired 1,373 shares of common stock under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on December 31, 2025.
• Additionally, 240,932 stock options were granted on January 2, 2026, with an exercise price of $11.82 per share and an expiration date of January 1, 2036.
• These stock options will vest over four years, with 1/48 vesting monthly beginning on the one-month anniversary of the grant date, subject to continued service.
• Following these transactions, Kaiser beneficially owns 271,918 shares of common stock and 240,932 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grants of significant equity awards to a key executive are generally positive, indicating confidence in the executive's role and aligning their interests with long-term company performance. This is a standard compensation practice aimed at retention and motivation.

Positives

• Significant equity grants (79,112 RSUs and 240,932 stock options) to a key executive, Peter Kaiser, align management's interests with long-term shareholder value creation.
• The multi-year vesting schedules (3 years for RSUs, 4 years for options) promote executive retention and sustained performance.
• The acquisition of 1,373 shares through the Employee Stock Purchase Plan demonstrates continued executive investment in the company.

Future Outlook

The multi-year vesting schedules for the granted RSUs and stock options indicate a long-term commitment to executive retention and performance incentives, aligning with future strategic goals.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology and pharmaceutical industry of using equity compensation, such as restricted stock units and stock options, to attract, retain, and incentivize key executives. Such grants are common for Chief Development Officers, whose roles are critical in advancing product pipelines and securing regulatory approvals, directly impacting a company's long-term value.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor dilution from new share issuance upon RSU vesting and option exercise, but also benefits from executive retention and performance alignment.
• Employees: Reinforces the company's commitment to equity-based compensation programs.
• Peter Kaiser (Reporting Person): Significant increase in potential future compensation and ownership stake, subject to vesting and company performance.

Next Steps

• Vesting of 1/3 of the RSUs on the one-year anniversary of January 2, 2026, and annually thereafter for two more years.
• Monthly vesting of 1/48 of the stock options beginning on the one-month anniversary of January 2, 2026, over four years.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Peter Kaiser, Chief Development Officer, Form 4, insider transaction, restricted stock units, RSUs, stock options, equity grant, executive compensation, employee stock purchase plan, ESPP, beneficial ownership